

# *Community pharmacist led medication reviews in the UK: a scoping review of the medicines use review and the new medicine service literatures*

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Stewart, D., Whittlesea, C., Dhital, R., Newbould, L. and McCambridge, J. (2020) Community pharmacist led medication reviews in the UK: a scoping review of the medicines use review and the new medicine service literatures. *Research in Social & Administrative Pharmacy*, 16 (2). pp. 111-122. ISSN 1551-7411 doi: 10.1016/j.sapharm.2019.04.010 Available at <https://centaur.reading.ac.uk/83527/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1016/j.sapharm.2019.04.010>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in

the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**


Central Archive at the University of Reading

Reading's research outputs online

# Accepted Manuscript

Community pharmacist led medication reviews in the UK: A scoping review of the medicines use review and the new medicine service literatures

Duncan Stewart, Cate Whittlesea, Ranjita Dhital, Louise Newbould, Jim McCambridge



PII: S1551-7411(18)30860-X

DOI: <https://doi.org/10.1016/j.sapharm.2019.04.010>

Reference: RSAP 1256

To appear in: *Research in Social & Administrative Pharmacy*

Received Date: 7 October 2018

Revised Date: 9 April 2019

Accepted Date: 14 April 2019

Please cite this article as: Stewart D, Whittlesea C, Dhital R, Newbould L, McCambridge J, Community pharmacist led medication reviews in the UK: A scoping review of the medicines use review and the new medicine service literatures, *Research in Social & Administrative Pharmacy* (2019), doi: <https://doi.org/10.1016/j.sapharm.2019.04.010>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**COMMUNITY PHARMACIST LED MEDICATION REVIEWS IN THE UK: A SCOPING REVIEW OF THE  
MEDICINES USE REVIEW AND THE NEW MEDICINE SERVICE LITERATURES**

\*Duncan Stewart<sup>a</sup>, Cate Whittlesea<sup>b</sup>, Ranjita Dhital<sup>c</sup>, Louise Newbould<sup>a</sup>, Jim McCambridge<sup>a</sup>

<sup>a</sup>Department of Health Sciences, ARRC Building, University of York, Heslington, York, YO10 5DD, UK

<sup>b</sup>School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK

<sup>c</sup>School of Pharmacy, University of Reading, Harry Nursten Building, PO Box 226, Whiteknights,  
Reading, Berkshire RG6 6AP, UK

\*Corresponding author: duncan.stewart@york.ac.uk

**ABSTRACT**

*Background:* Medicines Use Reviews (MURs) and the New Medicine Service (NMS) are services delivered by UK community pharmacists to improve adherence, improve patient understanding of their medicines and reduce medicines wastage.

*Aim:* In this scoping review we aim to identify, map and critically examine the nature of existing empirical evidence in peer reviewed journals relating to MUR and NMS consultations.

*Method:* Systematic searches identified the available MUR and NMS empirical literature. We sought data on barriers and facilitators to conducting MUR or NMS consultations, the perceptions of pharmacists and patients, the conduct of consultations, and outcomes of consultations. Searches from 2005 (when MURs were introduced) to May 2018 were conducted in MEDLINE, PsycINFO, Embase and Scopus databases. Data were extracted into Excel for examination of study characteristics, participant characteristics, type of intervention/services delivered and key study quantitative and/or qualitative findings.

*Results:* Forty-one papers from 37 studies met the inclusion criteria: 28 papers were of MURs, 10 of NMS and 3 for both services. Studies focused on the introduction and implementation of these services, with little attention to outcomes for patients; effectiveness was not evaluated beyond in a single NMS RCT. Observational data indicated that pharmacists and patients view MURs and the NMS positively, despite challenges implementing these services and apparent lack of communication between pharmacists and GPs. Consultations were reported to be short, typically 10-12 minutes, characterised by limited engagement with patients and their health problems. The extent and nature of advice on health behaviours during consultations or other content was rarely examined.

*Conclusion:* The research literature on MURs and the NMS has developed slowly. There is much scope for further research attention to developing more patient-centred care.

**Keywords:** Community pharmacy; Medicines Use Review (MUR); New Medicine Service (NMS); scoping review

## COMMUNITY PHARMACIST LED MEDICATION REVIEWS IN THE UK: A SCOPING REVIEW OF THE MEDICINES USE REVIEW AND THE NEW MEDICINE SERVICE LITERATURES

### INTRODUCTION

Medication reviews are intended to improve the quality, safety and appropriate use of medicines<sup>1</sup>. There is an extensive international literature to demonstrate the effectiveness of pharmacist delivered medication reviews. For example, reduced health problems, increased medication adherence and quality of life are reported consistently in systematic reviews<sup>2,3</sup>. Interpreting the findings of these reviews in relation to the specific context of UK community pharmacy is challenging. Differences in terminology and service configurations across countries are apparent, and meta-analyses often include pharmacist interventions from a mix of clinical settings and do not present effect sizes for community pharmacies alone<sup>2,3</sup>. There is also a large degree of heterogeneity in intervention content and delivery models within and across countries<sup>3</sup>, including Medicines Therapy Management services in the US<sup>4</sup> and Home Medication Review in Australia<sup>5</sup> which have similarities to UK pharmacy-led medicines review services.

Since 2005 all community pharmacists in the UK are contracted by the NHS to deliver essential services (such as dispensing). A second tier of 'advanced' contracted services includes Medicines Use Reviews (MURs) and the New Medicine Service (NMS), requiring community pharmacists who chose to deliver them to be appropriately trained and to meet specified service requirements<sup>6</sup>; these services are free to patients. Remuneration for contracted pharmacies from the NHS is £28 per MUR, up to a maximum of 400 per year, and up to £28 per NMS depending on numbers completed<sup>7</sup>. The purposes of MURs are to improve patients' understanding of their medicines and adherence, particularly among those with chronic conditions, highlight problematic side effects and propose solutions where appropriate, and to reduce medicines wastage<sup>8</sup>. The NMS supports people with long-term conditions and newly prescribed medication improve their medicines adherence, and there is also an explicit aim for the NMS to support patients make decisions about their treatment and self-management<sup>9</sup>. Most trials and other evaluation studies typically examine medication reviews for specific health conditions. Studies of medication reviews, of the types delivered by UK community pharmacists, which could include medicines for a range of conditions, are much less common. Thus, in one review, only five studies (4 RCTs and 1 prospective cohort study) were classified as MUR type adherence reviews delivered in a pharmacy, and most interventions included were disease specific<sup>3</sup>.

Extending the community pharmacist role in the UK beyond traditional dispensing is valued as an opportunity to demonstrate the worth, and further develop the skills, of the profession<sup>10</sup>. Among patients, the range of pharmacists' skills and training can be under-appreciated, to the extent that this can be a barrier to discussion of health behaviours<sup>11</sup>. Some qualitative studies report that patients' perceptions of pharmacists as appropriately skilled to provide medicines related information and care are influenced positively by having already experienced medication reviews<sup>10</sup>. Much hinges on individual pharmacist's communication and interpersonal skills, which are noted to be a source of variability in the conduct of medication reviews<sup>10</sup>. It is, therefore, not surprising that skills in behaviour change and communication strategies are identified as training needs<sup>10, 12</sup>, particularly for longer qualified pharmacists whose training predates attempts to increase attention to these elements<sup>12</sup>.

Community pharmacies offer a range of public health services, including sexual health screening, smoking cessation and alcohol interventions<sup>13</sup>. Delivery of these services during the course of routine NHS contacts is encouraged<sup>14</sup> and community pharmacies are well placed to provide them<sup>15</sup>; current MUR/NMS service specifications require pharmacists to ask patients about these and document any advice given. A systematic review of community pharmacist views found broad support for an increased public health role, but training needs and lack of confidence in how to intervene to support health behaviour change were also reported<sup>16</sup>. Medication reviews provide valuable opportunities to discuss with patients the possible consequences of specific behaviours for the effectiveness of medications, and for their health more generally. Potentially, this could be more comprehensive, and use more sophisticated methods, than the 'advice giving' associated with dispensing related interactions with patients<sup>17</sup>. This is congruent with General Pharmaceutical Council practice standards that place the interests and perspectives of the patient at the heart of patient consultations<sup>18</sup>. Informed by the Medication Related Consultation Framework (MRCF)<sup>19</sup>, these standards detail how pharmacists can use core skills to make their consultations about medications more patient-centred. The expectation is that all pharmacists are working towards, or have achieved, the required consultation skills which underpin these standards<sup>20</sup>.

This aim of this scoping review was to identify and examine existing empirical evidence in peer-reviewed journals relating to MUR and NMS consultations delivered by community pharmacists in the UK. Objectives were to: (1) identify and summarise the findings of existing MUR and NMS studies; (2) examine key features of these services, including barriers and facilitators to implementation (3) identify limitations and gaps in this literature; (4) identify any policy and practice implications based on existing findings.

## METHOD

We used systematic searches to identify and map all of the available MUR and NMS empirical literature in a scoping review. Within this mapping exercise, we sought data on the conduct of MUR and NMS consultations, the perceptions of pharmacists and patients, and the outcomes of consultations.

### *Inclusion and exclusion criteria*

Searches of primary research studies published in journal articles between 2005 (when MURs were introduced; the NMS was introduced in 2011) and May 2018 were conducted in MEDLINE, PsycINFO, Embase and Scopus databases, selected to achieve broad coverage of the review topic. Searches were limited to empirical studies with at least some data specific to these services. Reviews, articles with no primary data, and studies of similar non-UK services were excluded. No restrictions on study design were applied.

### *Search strategy*

Search terms for each database were 'medicine\* use review', 'MUR', 'new medicine service' and 'NMS'. Titles and abstracts of papers for potential inclusion were screened independently by two co-authors (DS & LN). Disagreements or uncertainties about specific papers were resolved by discussion with a third co-author (JM). Reference lists of identified articles relevant to the review but rejected because of exclusion criteria, and reference lists of included articles, were manually searched for additional eligible studies.

### *Extraction and analysis*

An Excel data extraction form was used to record year of publication, type of services delivered, study objectives, design and methodology, sample type and size, data collection time frame, and key study quantitative and/or qualitative findings. Systematic mapping of extracted data against these headings was conducted by one co-author (DS), and the content checked by the other co-authors. A narrative synthesis was undertaken to meet the study objectives. As a scoping review, the quality of studies was not evaluated formally.

## RESULTS

A total of 461 articles were identified through database searching, and an additional 6 from hand searches (Figure 1). After removal of duplicates, 141 titles and abstracts were screened, from which



46 full text papers were assessed for eligibility. Five studies were excluded: no empirical data (n=3); not MUR/NMS (n=1); a study of recruitment difficulties to a feasibility study already included in this review (n=1). Of the 41 papers included in the review, 28 were of MURs, 10 of NMS and 3 for both services.

The characteristics of the 41 MUR and NMS papers are described in Tables 1-5. Few studies employed an RCT or quasi-experimental design: one study (two papers examining effectiveness and cost-effectiveness) was an RCT<sup>21, 22</sup>, one was a small (randomised) feasibility study<sup>23</sup>, and another recruited a non-randomised control group<sup>24</sup>. Three papers exclusively examined secondary data from pharmacy records<sup>25-27</sup>. A further five mixed methods studies used secondary data in combination with other (mainly qualitative) data collection<sup>28-32</sup>. The remainder of papers were from qualitative studies (n=14), including four papers from the same study<sup>17, 33-35</sup>, and from surveys (n=15).

#### *Barriers and facilitators to implementation*

A number of studies concluded that health system factors contribute to variable levels of integration of MURs into routine patient care. In particular, studies using observation of consultations, interviews and surveys identified lack of communication and collaboration between community pharmacists and GPs<sup>29, 33, 36</sup> as a barrier to implementation and thus limiting the potential benefit to patients. Similarly, poorly developed relationships with GPs identified through observation and interviews<sup>37, 38</sup> and perceived lack of interest and awareness (from interviews and focus groups) by GPs<sup>39, 40</sup> have been reported to impede implementation of the (more recent) NMS.

The organisational setting of the pharmacy is an important factor facilitating the uptake of MURs, with experiences differing by pharmacy type. There is evidence for contrasting approaches to enhanced services in multiples and independents<sup>25, 28, 29, 41</sup>, confirmed by analysis of national MUR data showing more extensive adoption in the former<sup>30</sup>, perhaps driven by internal company pressures to achieve MUR targets<sup>42</sup>. A retrospective study of pharmacy records found significantly more patients per pharmacy were seen for targeted respiratory MURs in Healthy Living Pharmacies<sup>31</sup>. The numbers of MURs performed by pharmacists varies<sup>32</sup> and appears to be affected by the pharmacists' working hours and whether store based rather than locum pharmacists<sup>43</sup>. Availability of a consultation area suitable for performing MURs and pharmacists having sufficient time available to perform them are also identified as influencing the number of MURs conducted<sup>43</sup>.

Some patient groups have more limited access to medication consultations, including the elderly<sup>44</sup>, and one survey found limited uptake in a rural community<sup>45</sup>. Perceived difficulties taking consent have been cited by pharmacists as the main reason for not undertaking MURs or the NMS with

young people and/or their carers<sup>46</sup>. More generally, one study reported that pharmacists avoid more complex cases (for example, with multiple conditions) because they were judged to be more difficult to recruit and would take more time to complete<sup>33</sup>. Patients from marginalised communities (e.g. people with disabilities, diagnosed with a serious mental illness, or with no fixed abode) are not always aware of enhanced pharmacy services but would welcome greater engagement, while pharmacists find it more difficult to identify, communicate with and accommodate the specific needs of these patients within the context of the busy pharmacy environment<sup>47</sup>.

#### *Patient perceptions*

Patients' perceptions of MURs and NMS are broadly positive<sup>34, 48</sup>. A survey of over 500 patients following an MUR (although the response rate was very low; 24%) found high levels of patient satisfaction with the service across a number of domains, even if some patients were initially reluctant to take part in a MUR<sup>49</sup>. Patients have reported learning more about their medicines and side effects after a MUR, and to have improved their compliance<sup>32, 50</sup>. More detailed examination of patient experiences using observation of MURs and patient interviews indicated that although patients appreciate the opportunity to discuss medication with a pharmacist, MUR consultations do not necessarily improve their knowledge of medicines or affect how they used them<sup>34</sup>. Patients have been found to value the two way dialogue with pharmacists and be able to ask questions<sup>51</sup>. Misalignment between patients' and pharmacists' framing of the purpose and potential benefits of the NMS has also been reported<sup>52</sup>, as well as variations in the information available to patients about the nature of pharmacist-patient roles<sup>53</sup>. More general expectations of these services among pharmacists and the public have been found to be similarly high to each other<sup>48</sup>.

#### *Pharmacist perceptions*

Overall, community pharmacists are positive about the idea of MUR and NMS services, and view them as an opportunity to use their skills. Studies report community pharmacists' confidence to undertake MURs to be high<sup>41, 54</sup> and perceive the service to be of value to patients<sup>43</sup>. Pharmacists appear to underestimate the willingness of patients compared to the general public to engage with enhanced pharmacy services<sup>48</sup>. One small survey found opinions differed as to whether MURs constitute a tick-box exercise<sup>55</sup>, but found agreement that MURs should strike a balance between clinical (e.g. ensuring patients take correct medication) and behavioural (e.g. using medication in the correct way) content.

Despite pharmacists holding positive views about the potential value of the NMS<sup>40</sup>, reflections on practice suggest they are not convinced of its necessity for some patients. Qualitative evidence

indicated that many consultations did not identify any problems with the patients' medicines, raising questions about targeting<sup>37</sup>. Thus, focus groups with community pharmacists have identified potential benefits of the NMS service, but opinions of implementing the NMS in practice are much more mixed<sup>38</sup>. Prior to the introduction of the NMS, payment structure, speed of implementation, and the availability of supporting materials were cited by pharmacists as potential barriers to implementation<sup>40</sup>. The influence of these or other environmental factors on practice has not been examined in more recent literature.

#### *Conduct of consultations*

The duration of these consultations is short. A survey of 341 pharmacists estimated MUR consultations to take an average of 10 minutes and the NMS an average of 12 minutes, durations which were found to be acceptable to both pharmacists and patients<sup>48</sup>. Ethnographic observations of 54 MUR consultations and interviews with 34 MUR patients and 5 pharmacists<sup>17</sup> had a number of key findings. MUR consultations were brief and involved mainly closed questions to enable quick and easy completion of the MUR form; the MUR was often introduced as a quick check of medicines. Opportunities for patients to ask questions were minimised. Pharmacists were reluctant to engage in discussion of patients' illnesses, which patients often raised. Thus, the consultations did not address how patients might manage their illness better with their medicines, and had little impact on medicine use. From this study, it is doubtful that the depth of engagement with patients and their health problems during consultations is sufficient to fulfil the purposes of MURs beyond checking safety. Pragmatic constraints of workload and pharmacy organisation were reported by pharmacists as barriers to effective MUR implementation.

In contrast, one small observational study of MUR consultations (n=7) reported that patients valued discussion with the pharmacist, when it involved an exchange of information rather than simply information giving<sup>56</sup>. Similarly, standardised documentation for MURs may not constrain pharmacists' autonomy to adapt the material, to avoid a formulaic approach to medication discussions<sup>42</sup>. MUR quality indicators have been proposed to improve recording of consultations having been delivered<sup>57</sup>.

Concern has been expressed that opportunities for NMS consultations are more limited than originally intended<sup>26</sup>. This is supported by a pharmacist survey that found low levels of NMS provision for patients prescribed oral anti-coagulants for stroke prevention in atrial fibrillation<sup>58</sup>. Observations and interviews with patients suggest NMS consultations to be a pharmacist led questioning of the patient, with variation in the extent to which pharmacists keep to a formal NMS discussion schedule<sup>52</sup>. Focus groups with pharmacists before NMS implementation identified

interview techniques and communication skills as being important for the successful delivery of NMS but not something requiring further training<sup>40</sup>. Pharmacists also had positive attitudes to providing the service, seeing it as an opportunity to use their clinical skills to benefit patients. In practice, the importance of pharmacists' communication and interpersonal skills is underlined by the pragmatic approaches taken to implementing medication reviews. An observational study of NMS delivery reported pharmacists using strategies to persuade patients to have NMS and attempting to keep an informal tone to discussions<sup>37</sup>. The NMS question guide was thus adapted to suit conversation flow and pharmacists' perceptions of the purpose of NMS. Whilst some managed patient discussions competently, this study also found evidence that pharmacists needed to enhance their consultation and communication skills to ensure that NMS consultations are patient-centred. For example, some regarded NMS to be information giving, rather than exploring patient understanding of medication, calling into question how patient-centred the service delivered can be expected to be. Using a similar methodology Waring et al. reported that not all pharmacists were equally skilled at communicating with their patients during NMS consultations, with some more able to go 'off-script' to ask about lifestyle factors<sup>59</sup>. Significantly, these pharmacists tended to be more experienced and concerned with developing a relationship with patients.

Very little information is available in the literature on the extent of discussion or advice on health behaviours during consultations. A pharmacist completed survey reported over a fifth of NMS patients received advice on such issues, most commonly on diet, with alcohol and smoking advice provided to around 40% of these patients<sup>60</sup>. Such shortcomings extend beyond the conduct of MURs and the NMS, indicating broader challenges to moving from a traditional community pharmacist role to consistent adoption of patient-centred approaches to practice. Interviews with 15 community pharmacists suggested a perception that cardiovascular disease patients may react negatively to the uninvited offer of health behaviour advice, and in turn made pharmacists reluctant to discuss broader issues of relevance to patients' health<sup>61</sup>. Some pharmacists in the sample felt that they did not receive appropriate skills training to offer patients such advice, although confidence to do this appeared to develop over time. Management of long term conditions has been described by pharmacists as identifying medication issues and informing/educating patients about it, rather than actively involving patients in decision making about their medication<sup>62</sup>. A more recent focus group and interview study<sup>63</sup> with a range of pharmacists and staff, including 6 early career community pharmacists and 8 community pharmacy pre-registration tutors reinforced the need to avoid technical language during consultations, avoiding being overly friendly (pharmacists perceived this to be off-putting to patients) and flexibility to adapt communication style to individual patients. Thus, overly formalised interventions cannot facilitate patient centred care.

### Outcomes

The majority of studies were qualitative or surveys and typically of small scale, and few studies evaluated outcomes of MURs or the NMS in any way. To date only one randomised trial (of NMS) has been conducted. This trial recruited 504 participants, allocated to NMS or usual care, and measured self-reported medication adherence at 10 weeks follow-up, defined as missing no doses without the advice of a medical professional in the previous 7 days<sup>21</sup>. NMS significantly increased the proportion of patients adhering to their new medicine by about 10%, and was significant in intention to treat analyses and after adjustment for missing data. Economic modelling of adherence outcomes, using NHS and non-NHS resource use costs and costs of the intervention costs, found health benefit at lower cost attributable to NMS; a mean of 0.05 more QALYs per patient, at a mean reduced cost of -£144<sup>22</sup>. Although this was designed as a pragmatic trial, it is unclear how far these findings may generalise to the outcomes that may be expected when NMS is delivered in routine practice.

A range of outcomes have been reported by studies not robustly designed to identify outcomes. A quasi-experimental study of post-hospital counselling and community pharmacist MURs improved patients' knowledge of their medication, but was undermined by less than half of patients for whom a MUR was recommended actually receiving one<sup>24</sup>; the primary reason was patients having their medicine delivered to their home, and thus not requiring a visit to a community pharmacy. Lack of mobility has also been identified as a barrier to conducting post-hospital discharge MURs in a small feasibility trial<sup>23</sup>. In a large survey-based evaluation of hospital referrals to a community pharmacy follow-up service, MUR (n=288) or NMS (n=241) consultations were the most common types of service provided (if provided at all), with results indicating that patients receiving a follow-up consultation (of any type) may have lower rates of readmission and shorter hospital stays<sup>27</sup>. A patient survey (n=232, from 4 community pharmacies) found that those who had received an advanced pharmacy service, such as a MUR, reported greater medicines adherence and satisfaction with medicine related information<sup>64</sup>. There may be unintended consequences to pharmacists spending time undertaking these consultations: support-staff report feeling frustrated when left to explain to patients that the pharmacist is not available because they are conducting an MUR<sup>35</sup>.

### DISCUSSION

The MUR and NMS literature largely focuses on the introduction and early implementation of these services, with little detailed attention to process and outcomes for patients. The international literature of pharmacist- led medication reviews convincingly shows improved disease-specific and medication adherence outcomes<sup>2</sup>, but beyond the single NMS RCT<sup>21</sup> the effectiveness of UK medication related advanced services has not been evaluated, despite on-going challenges to

successful implementation<sup>65</sup>. Confidence that the specific aims of MUR and NMS consultations<sup>8,9</sup> will be achieved in practice is, therefore, limited by the research evidence available.

There is enthusiasm for MURs and the NMS from both pharmacists and patients as a means to improve the way medication is taken, and by implication effectiveness and safety<sup>34, 38, 41, 43, 48-50, 55</sup>. In practice, discussions of medicines appear to often involve one-way communication of information from pharmacists to patients<sup>17, 37, 52</sup>, described previously as an 'educator/informer' role<sup>10</sup>, with limited exploration of patient perspectives or attempt to gain the broader understanding of patient circumstances<sup>17, 33, 34, 59</sup> that should be expected to provide secure foundations for consultation practice<sup>18</sup>. There is scant information in the literature about how community pharmacists perceive implementation of these services to have changed or developed their practice, or how they may benefit patients. Similarly, very little is known about patients' perspectives of whether and how medicine consultations influence their own behaviour. These are essential elements to better understanding mechanisms that underpin delivery and outcomes of medication reviews, and could usefully inform future advances in UK community pharmacy practice.

Development and roll-out of consultations skills training for pharmacists<sup>66</sup> occurred in 2014, after the introduction of MURs and the NMS. In such circumstances it might be expected that the conduct of the services reported in earlier studies does not reflect practice standards aspirations. Pharmacists' skills in behaviour change and in communication have been identified as training needs<sup>10, 12</sup>, particularly for longer qualified pharmacists whose training predates attempts to increase attention to these elements<sup>12</sup>. Turning person-centred rhetoric into tangible experiences of the delivery of medication reviews involves supporting pharmacists to engage with patients as active participants in decision making and ensuring that any information and advice offered is meaningful and appropriate to their needs<sup>67, 68</sup>. Future initiatives will also need to account for external factors that influence what happens in consultations, beyond the control of individual community pharmacists, including the organisational cultures of different types of pharmacy, funding structures and targets, constraints on pharmacists' time and relationships with GPs. Secondary analysis of data published after the searches for this review were completed shows that implementation of the NMS can be achieved with minimal impact on GP services<sup>61</sup>.

Examples of more person-centred practice can be found in the literature<sup>37, 42, 55, 56, 59</sup> and include: (a) avoiding using consultations as a medicine checking exercise; (b) adopting a flexible and informal communication style; (c) asking open questions; (d) exploring issues relevant to patients' condition(s); (e) checking patient understanding of issues raised in consultations; (f) using

consultations to build relationships. Some pharmacists are skilled at adapting the standardised discussion schedules to the individual circumstances of the patient<sup>37, 42</sup>. Greater experience may be a factor<sup>59</sup>, but the reasons for such varied practice and identification of mechanisms to improve it require further research and elaboration.

Pharmacists typically view addressing patient's broader health as important and a legitimate part of their role, but secondary to medicine related issues<sup>16</sup>. A range of barriers to pharmacists raising and discussing lifestyle factors have been identified by previous international reviews, including lack of time, low confidence, insufficient skills, lack of demand, and perceptions among pharmacists that patients may react negatively to unwanted advice<sup>16, 69</sup>. Thus attention to medication use unsurprisingly lies at the heart of medicines consultations. Recognising the public health potential of community pharmacies, the Healthy Living Pharmacy framework, encompassing workforce development, improving premises and community engagement, was introduced to foster health promotion activities after successful piloting<sup>31</sup>. The impact of this initiative on the delivery of medication consultations, and on the barriers to person-centred practice identified above, has yet to be examined. Evidence from this review indicates that attention to health behaviours is often not included in medication consultations, or is considered incidental to the primary purposes of the service provision.

Improving the quality of life and care for the rising numbers of people with long term conditions is a UK policy priority<sup>14, 70, 71</sup>. This presents opportunities for pharmacists to play a major role in improving the health and wellbeing of this population, including optimising the contributions of routine pharmacy services such as medication reviews. There is untapped potential in utilising existing medication review consultations to address patient agendas in the manner proposed by the policy documents and in the training materials developed for community pharmacists.

There are some limitations to this review. Although we aimed to map the existing MUR and NMS literature, we chose to limit our searches to empirical data in peer reviewed journals; grey literature searches may have identified further information about these services. Nevertheless, our inclusion criteria were broad and identified studies with a diverse range of methodologies. This proved useful in highlighting significant gaps in the available evidence, but limited meaningful comparisons between studies. As a scoping review, the quality of included studies was not evaluated formally.

## Conclusion

Recent debate points to uncertainties over the future form of medicine reviews in the UK<sup>73, 74</sup>. It will benefit the health of the population if decisions about these and other commissioned pharmacy services are informed by high quality evidence. Despite finding much scope for concern about the

conduct of MURs and the NMS, evidence from this review indicates also scope for re-alignment of MURs and the NMS (or their future iterations) with the core values and skillsets espoused in the professional standards for patient-centred care. A recent Cochrane review of pharmacy services for non-hospitalised patients contained little data directly relevant to this review, and emphasised the heterogeneity of data in similar ways to earlier reviews<sup>75</sup>. It also drew attention to the potential for role substitution and anticipated cost savings when health systems broaden the expectations being placed on pharmacists. Any sought economic benefits will not be realised, however, unless pharmacists are able to help patients manage their own health. This entails conducting consultations with a focus squarely on the needs and goals of the patient, including addressing concerns presented and the health outcomes valued by patients, as established from patients' experiences of their medicines and conditions, and what they want from the provision of these services. Simple enquiry and exploration to understand what is important to the individual patient are consistent with pharmacist professional values, welcomed by patients, and achievable to deliver within existing consultation frameworks.



Table 1: Characteristics of RCTs and quasi-experimental studies

Study	NMS/MUR	Objective(s)	Design	Sample	Time frame	Key findings
Elliott et al. 2016 <sup>21</sup>	NMS	Examine the effectiveness of the NMS on medication adherence compared with normal practice	RCT	504 patients in 46 community pharmacies	2012-2013	A significantly greater proportion of NMS patients were adherent compared to normal practice (71% vs 61%) at 10 week follow-up. Adjusted OR for increased adherence was 1.67 in favour of the NMS arm.
Elliott et al. 2017 <sup>22</sup>	NMS	Examine the effectiveness of the NMS on medication adherence compared with normal practice	RCT	504 patients in 46 community pharmacies	2012-2013	NMS generated a mean of 0.05 more QALYs per patient, at a mean reduced cost of -£144 , and a probability of 0.78 [incremental cost-effectiveness ratio (ICER) -£3166 per QALY]
Elson et al. 2017 <sup>24</sup>	MUR	Determine the effects of targeted hospital pharmacist counselling or post-discharge MURs on patients' knowledge of medication	Controlled (non-randomised) trial	101 patients	2013	Patients who received pharmacist counselling were more likely to report being told the purpose of their new medicine and how to take it. Fewer than half of allocated to receive a MUR actually received one.
Ramsbottom et al. 2018 <sup>23</sup>	MUR	Evaluate the potential clinical and economic impact of community pharmacists' interventions during post-hospital discharge MURs	RCT feasibility study	20 patients	Not stated	An average of 2 interventions were instigated per MUR. The most common was to provide information to improve patient understanding of their medication and how to use it in the most effective, convenient and safe way. Indicative cost savings were found.

Table 2: Characteristics of secondary data analysis studies

Study	NMS/MUR	Objective(s)	Design	Sample	Time frame	Key findings
Blenkinsopp et al. 2008 <sup>25</sup>	MUR	Evaluate the first three years of the MUR service provision	Longitudinal analysis of pharmacy MUR provision records	1,090 pharmacies	2005-2008	The number of MURs and pharmacies providing them increased over successive years. Independents were less likely than multiples to provide MURs, and those independents that did conducted fewer.
Wells et al. 2014 <sup>26</sup>	NMS	Investigate the proportion of prescription items eligible for the NMS and if eligibility is affected by pharmacies' proximity to GP practices	Cross sectional analysis of prescription data	8005 prescription items	2013	0.25% of prescription items were eligible for the NMS, lower than the assumed 0.5%. The opportunity rate for NMS was 0.21% of items, as some eligible items did not translate into opportunities to offer the service. GP proximity made no difference.
Nazar et al. 2016 <sup>27</sup>	NMS/MUR	Evaluate an electronic patient referral system from hospital to community pharmacies	Cross sectional analysis of hospital referral data	2029 patients	2014-2015	Only 31% of patients received a community pharmacist follow-up consultation. Most referred patients were over 60 years of age and referred for a MUR or the NMS. Patients who received a follow-up consultation had fewer readmissions and shorter hospital stays.

Table 3: Characteristics of mixed methods studies

Study	NMS/MUR	Objective(s)	Design	Sample	Time frame	Key findings
Blenkinsopp et al. 2007 <sup>28</sup>	MUR	Measure MUR provision in first year of implementation	Postal survey; cross sectional analysis of pharmacy records; interviews	1,072 pharmacies; 29 primary care organisations	2005-2006	<i>Quantitative:</i> Uptake and spread of MURs was low, and dominated by multiples. <i>Qualitative:</i> Relationships between pharmacists and GPs a key barrier to implementation.
Bradley et al. 2008 <sup>29</sup>	MUR	Explore and identify the key determinants influencing uptake of MURs	Survey, interviews and cross sectional analysis of MUR data	MUR data from 9872 pharmacies; Survey (n=216) of primary care organisations; stakeholder interviews (n=43)	2005-2007	<i>Quantitative:</i> Rates of MURs by multiples were almost twice that of independents. Survey respondents perceived lack of GP support to be the greatest barrier to MUR implementation. <i>Qualitative:</i> Organisational pressure within multiple pharmacies was identified as driving MUR activity.
Portlock et al. 2009 <sup>32</sup>	MUR	Evaluate MUR interventions for asthma	MUR outcome audit; Feedback forms	965 patients; 28 pharmacists; 15 GPs	2007	<i>Quantitative:</i> MUR numbers varied markedly between pharmacies. Adherence was greater among patients who had received a GP review in the past year. MURs increased patient knowledge about their condition and treatment. <i>Qualitative:</i> Patient feedback was positive about overall impression of the service, privacy, demonstration of inhalers, explanations of medication and convenience.

Brown et al. 2014 <sup>31</sup>	MUR	Assess the impact of the healthy living pharmacy (HLP) framework on service provision and staff engagement	Cross sectional analysis of pharmacy records; interviews	17 HLPs and 19 non-HLPs; 38 community pharmacy staff, including 25 pharmacists	2011-2012	<i>Quantitative:</i> Significantly more clients per pharmacy were seen in HLPs than non-HLPs for MURs (medians: 29 vs 11). <i>Qualitative:</i> None relevant to MURs.
Hann et al. 2017 <sup>30</sup>	MUR	Identify factors associated with variation in the volume of services delivered by community pharmacies	Longitudinal analysis of national MUR data; postal survey	10,454 pharmacies; 284 pharmacy representatives	2011-2016	<i>Quantitative:</i> Greater volume of MURs was associated with pharmacy ownership type (large chains/supermarkets vs independents), greater dispensing volume, and lower disease prevalence. Survey responses supported these findings, with MUR volume also associated with weekly opening hours and lower asthma prevalence.

Table 4: Characteristics of surveys

Study	NMS/MUR	Objective(s)	Design	Sample	Time frame	Key findings
Wilcock & Harding 2007 <sup>36</sup>	MUR	Explore GPs' perceptions of MURs	Self-complete survey	52 GPs	2007	GPs reported good relationships with community pharmacists, but had negative views about MURs. Lack of clarity about the purpose of MURs and concerns about pharmacists advising on clinical rather than practical issues were raised.
Latif & Boardman 2008 <sup>43</sup>	MUR	Investigate factors that influence the number of MURs performed by community pharmacists and pharmacists' attitudes towards the service	Postal survey	167 community pharmacists from one pharmacy chain	2006	More MURs were performed by store based pharmacists than locums, and by those with access to a consultation room. Most respondents felt that MURs would be of benefit to patients, but reported concerns about GP opinions of the service, and lack of time and support staff to conduct MURs.
James et al. 2008 <sup>57</sup>	MUR	Develop criteria for assessment of MUR referral documentation	Delphi study	16 Delphi panellists	2006	Twenty MUR quality indicators were agreed.
Youssef et al. 2009 <sup>54</sup>	MUR	Evaluate MUR workshops for undergraduate pharmacy students	Self-complete survey	107 undergraduate pharmacy students	Not stated	Students would value demonstration of well and poorly conducted MURs, with real life case studies.
Harding & Wilcock 2010 <sup>55</sup>	MUR	Explore existing mechanism to ensure quality assurance of medicine use reviews (MURs), and to identify those parameters of an MUR that community pharmacists consider as indicators of quality	Postal survey	50 community pharmacists	2008	Pharmacists exercise their judgement about whether to undertake a MUR with a patient. Pharmacists shared a common sense of poor practice, but were less clear about defining a well conducted MUR.

Youssef et al. 2010 <sup>50</sup>	MUR	Examine patient benefit following MURs	Postal survey	81 patients	2008	Two thirds of patients thought they learnt more about their medicines after the MUR, 58% thought the MUR increased awareness of medicine side effects, and 83% thought the MUR improved their compliance. Older patients perceived more benefit.
Tucker 2013 <sup>41</sup>	MUR	Explore the range of dermatology MURs undertaken by pharmacists and their confidence in dealing with the provision of advice to patients.	Postal survey	870 community pharmacists	Not stated	Over 40% of pharmacists undertook dermatology MURs and rated themselves as confident in this role. More MURs were conducted by pharmacists employed by multiples.
Merks et al. 2016 <sup>45</sup>	MUR	Assess patients' opinion about prevalence of pharmaceutical services available in a community pharmacy in a rural area and identify appropriate action(s) to enhance patients' awareness of pharmaceutical services in rural areas.	Self-complete Survey	103 patients	2015	Awareness of expanded pharmaceutical services was poor; MUR was the only advanced service used (by 13% of respondents), primarily by men.
Rodgers et al. 2016 <sup>48</sup>	NMS/MUR	Compare the perceptions of pharmacists and the general public on MURs and the NMS.	Street and postal surveys	1000 public respondents; 341 pharmacists	2012	Few from the public sample were aware of MURs or the NMS. Pharmacists estimated spending 10 minutes on MURs and 12 minutes on NMS; acceptable to both pharmacists and the public. Expectations of services increasing knowledge and understanding of medication were high, but did reflect public experiences of the services.

Twigg et al. 2016 <sup>64</sup>	MUR	Examine information needs and reported adherence of patients who received a community pharmacy advanced service.	Postal survey	232 patients from 4 community pharmacies	Not stated	All respondents desired further information about their prescribed medicines, particularly about potential medication problems. Satisfaction with information about medicines and adherence were significantly greater among patients who had received an advanced service, such as a MUR.
Cheema et al. 2017 <sup>60</sup>	NMS	Assess the impact of the NMS on medication use by patients starting a new medication for a long-term medical condition.	Pharmacist completed questionnaires	285 patients	2012	On the first NMS assessment, 82 patients reported drug-related problems of whom 58 received pharmacists' advice. At follow up 39 (67%) of these 58 patients reported resolution of problems compared to 17% of the patients who did not receive pharmacists' advice (OR=10.2).
Hamed et al. 2017 <sup>58</sup>	NMS	Assess community pharmacists' practice, knowledge and confidence in supporting patients' adherence as part of the NMS for patients on Oral Anti-Coagulants for stroke prevention in Atrial Fibrillation	On-line survey	257 patients	2014-2015	Priorities during the NMS consultation were to discuss actions to take when bleeding occurs and supporting adherence. Pharmacists were more confident in their knowledge, skills and access to resources for Vitamin-K Antagonists than for new oral anticoagulants.
Hindi et al. 2017 <sup>49</sup>	MUR	Develop, pilot, and utilize a MUR patient satisfaction questionnaire	Postal survey	505 patients	2016	Patients showed a high degree of overall satisfaction with MURs, even if initially reluctant to take part in one.

Rutter et al. 2017 <sup>44</sup>	MUR	Investigate the perspective of community pharmacists on the usefulness of and suitability of MUR referrals from hospital.	Postal survey	19 community pharmacists	Not stated	Barriers to implementation were failure or inability of patients to attend the pharmacy. Community pharmacists' views of the service were positive, but felt further medications information would be useful for referrals.
Aston et al 2018 <sup>46</sup>	NMS/MUR	Determine whether community pharmacists undertake MUR or NMS with children/their carers and identify the type of medication-related experiences presented to them when a child is taking long-term medication	Postal survey	76 community pharmacists	2015	MUR and NMS utilised by community pharmacists for children/carers. Presentations were for non-adherence including stopping medication and changing dose. Pharmacists were directly asked about dose, administration and adverse effects.



Table 5: Characteristics of qualitative studies


Study	NMS/MUR	Objective(s)	Design	Sample	Time frame	Key findings
Urban et al. 2008 <sup>39</sup>	MUR	Explore community pharmacists' experience of conducting MJRs	Interviews	21 community pharmacists	Not stated	Uncertainty about the best ways to select and recruit patients for MURs. Perception that MURs improve patient understanding and use of their medications. Perception that GPs have doubts about the value of MURs.
McDonald et al. 2010 <sup>42</sup>	MUR	Explore community pharmacists' reactions to the introduction of MURs	Interviews	49 community pharmacists	2007-2008	Support for MURs was high, although workload pressures hindered pharmacists ability to undertake them. Some pharmacists (from multiples) felt under pressure to meet MUR targets.
van den Berg M & Donyai 2010 <sup>53</sup>	MUR	Investigate the depiction of the patient-pharmacist power relationship within MUR patient information leaflets	Discourse analysis	11 leaflets	2006	A variety of terminology was used to describe MURs, with the intended cooperative nature of the service not fully described.
Latif et al. 2011 <sup>17</sup>	MUR	Understand the contribution of MURs to counselling practice	Observations, patient and pharmacy staff interviews	54 MURs, 34 patient interviews, 17 staff interviews, from 2 community pharmacies	2008-2009	MURs were short, with pharmacists asking mainly closed questions. Patients rarely asked questions. Knowledge and use of medicines was largely unaffected. Practical factors hindered MUR implementation.

Latif et al. 2013 <sup>33</sup>	MUR	Examine patient perspectives of MURs and GP-pharmacist collaboration	Observations and interviews	54 MURs, 34 patient interviews, 17 staff interviews, from 2 community pharmacies	2008-2009	Patients reported positive views about MURs. Little evidence of pharmacists and GPs working collaboratively. MURs conducted in isolation from other aspects of patient care. Potential for MURs to cause tensions with GPs.
Latif et al. 2013 <sup>34</sup>	MUR	Describe patients' perspective of the MUR service and what value that they derive from it.	Observations and interviews	34 patients from 2 community pharmacies	2008-2009	Patients were comfortable speaking with the pharmacist and the MUR provided reassurance about their medicines. The purpose of MURs was unclear to patients and did not improve their medicine knowledge or use.
Latif et al. 2013 <sup>35</sup>	MUR	Explore the impact and consequences of MURs on pharmacy support-staff	Observations and interviews	5 community pharmacists; 12 support staff	2008-2009	Some support-staff felt frustrated when left to explain to patients why the pharmacist was not available when carrying out an MUR.
van den Berg M & Donyai 2014 <sup>51</sup>	MUR	Develop a patient satisfaction conceptual framework	Observations and interviews	7 MURs and 15 patient interviews	2008-2010	Five themes identified: relationships with healthcare providers; attitudes towards healthcare providers; patients' experience of health, healthcare and medicines; patients' views of the MUR service; the logistics of the MUR service.

Wells et al. 2014 <sup>40</sup>	NMS	Explore pharmacists' views and experiences of the NMS prior to implementation to identify facilitators and barriers to its success	Focus groups and interviews	15 community pharmacists; 5 superintendent pharmacists	2011	Views of the NMS were positive. Potential barriers included lack of interest/awareness by GPs and the payment structure, speed of implementation, and absence of some support materials.
Lucas & Blenkinsopp 2015 <sup>38</sup>	NMS	Explore community pharmacists' experiences and perceptions of NMS	Interviews	14 community pharmacists	2012	Pharmacists perceived the NMS as beneficial, providing additional advice and reassurance to patients. The opportunity to utilise their professional expertise was welcomed, but different levels of collaborative working with GPs were reported.
Latif et al. 2016 <sup>37</sup>	NMS	Explore NMS implementation	Observations and interviews	47 community pharmacists and 11 GPs	2012-2013	Pharmacists were pragmatic, simplifying, and adapting the NMS to facilitate delivery. Pharmacists held positive views about the value of the NMS, but reported not identifying problems with medicines. Poor pharmacist-GP relationships impeded implementation.
Waring et al. 2016 <sup>59</sup>	NMS	Explore changing dynamics of pharmacist-patient power after introduction of the NMS	Observations and interviews	20 patients and 27 community pharmacists	2012-2013	NMS extends the 'pharmacy gaze' to further aspects of patients' health and lifestyle, beyond dispensing and advice giving, and results in greater complexity in pharmacist-patient relational power.

Latif et al. 2018 <sup>47</sup>	MUR	Explore the medicine needs of patients from marginalised communities and how services could better meet their requirements	Workshops and interviews	Workshops: 23 patients; 24 pharmacy professionals Interviews: 10 patients; 10 pharmacy staff	2016	Patients reported poor management of their conditions and problems with adherence. Experiences of pharmacy services were variable, with many experiencing discrimination or disadvantage.
Latif et al. 2018 <sup>52</sup>	NMS	Examine implementation of the NMS	Observation and interviews	Observation: 20 patients Interviews: 35 patients; 47 community pharmacists; 11 GPs	2012-2013	Patients were generally unaware of the NMS. Patients tended to report having no problems with their medicines or to adopt their own strategies for dealing with them. Consultations were generally passive and focussed on how patients were 'getting on' with their medication.

Figure 1: PRISMA flow chart of search strategy and article selection



## REFERENCES

1. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. *Br J Clin Pharm*. 2012;74:573-580.
2. Jokanovic N, Tan EC, Sudhakaran S, et al. Pharmacist-led medication review in community settings: An overview of systematic reviews. *Res Social Adm Pharm*. 2017;13:661-685.
3. Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. *Br J Clin Pharmacol*. 2014;77:102-115.
4. Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: A systematic review and meta-analysis. *JAMA Internal Medicine*. 2015;175:76-87.
5. Jokanovic N, Tan ECK, van den Bosch D, Kirkpatrick CM, Dooley MJ, Bell JS. Clinical medication review in Australia: A systematic review. *Res Social Adm Pharm*. 2016;12:384-418.
6. Department of Health and Social Care. Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013: Department of Health and Social Care; 2013.
7. Pharmaceutical Services Negotiating Committee. Advanced Service Payments; <https://psnc.org.uk/funding-and-statistics/funding-distribution/advanced-service-payments/>; Accessed 03.02.19
8. Pharmaceutical Services Negotiating Committee. MURs: the basics; <https://psnc.org.uk/services-commissioning/advanced-services/murs/murs-the-basics/>; Accessed 05.07.18.
9. Pharmaceutical Services Negotiating Committee. New Medicine Service (NMS); <https://psnc.org.uk/services-commissioning/advanced-services/nms/>; Accessed 05.07.18.
10. Hall NJ, Donovan G, Wilkes S. A qualitative synthesis of pharmacist, other health professional and lay perspectives on the role of community pharmacy in facilitating care for people with long-term conditions. *Res Social Adm Pharm*. 2018.
11. Anderson C, Blenkinsopp A, Armstrong M. Feedback from community pharmacy users on the contribution of community pharmacy to improving public's health: a systematic review of the peer reviewed and non-peer reviewed literature 1990-2002. *Health Expect*. 2004;7:191-202.
12. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. *J Public Health Med*. 2003;25:144-153.
13. Brown D, Portlock J, Rutter P, Nazar Z. From community pharmacy to healthy living pharmacy: positive early experiences from Portsmouth, England. *Res Social Adm Pharm*. 2014;10:72-87.
14. NHS England. NHS: Five year forward view 2014.
15. Brown TJ, Todd A, O'Malley C, et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. *BMJ Open*. 2016;6:e009828.
16. Eades CE, Ferguson JS, O'Carroll RE. Public health in community pharmacy: A systematic review of pharmacist and consumer views. *BMC Public Health*. 2011;11:582.
17. Latif A, Pollock K, Boardman HF. The contribution of the Medicines Use Review (MUR) consultation to counseling practice in community pharmacies. *Patient Educ Couns*. 2011;83:336-344.
18. General Pharmaceutical Council. Standards for pharmacy professionals. London: General Pharmaceutical Council; 2017.
19. Abdel-Tawab R, James DH, Fichtinger A, Clatworthy J, Horne R, Davies G. Development and validation of the Medication-Related Consultation Framework (MRCF). *Patient Educ Couns*. 2011;83:451-457.

20. Centre for Pharmacy Postgraduate Education. Consultation skills for pharmacy practice: taking a patient-centred approach. Manchester: CPPE; 2014.
21. Elliott RA, Boyd MJ, Salema NE, et al. Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: A pragmatic randomised controlled trial of the New Medicine Service. *BMJ Qual Saf.* 2016;25:747-758.
22. Elliott RA, Tanajewski L, Gkountouras G, et al. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice. *PharmacoEconomics.* 2017;35:1237-1255.
23. Ramsbottom H, Rutter P, Fitzpatrick R. Post discharge medicines use review (dMUR) service for older patients: Cost-savings from community pharmacist interventions. *Res Social Adm Pharm.* 2018;14:203-206.
24. Elson R, Cook H, Blenkinsopp A. Patients' knowledge of new medicines after discharge from hospital: What are the effects of hospital-based discharge counseling and community-based medicines use reviews (MURs)? *Res Social Adm Pharm.* 2017;13:628-633.
25. Blenkinsopp A, Bond C, Celino G, Inch J, Gray N. Medicines use review: Adoption and spread of a service innovation. *Int J Pharm Pract.* 2008;16:271-276.
26. Wells KM, Boyd MJ, Thornley T, Boardman HF. What proportion of prescription items dispensed in community pharmacies are eligible for the New Medicine Service? *BMC Health Serv Res.* 2014;14:115.
27. Nazar H, Brice S, Akhter N, et al. New transfer of care initiative of electronic referral from hospital to community pharmacy in England: a formative service evaluation. *BMJ open.* 2016;6:e012532.
28. Blenkinsopp A, Celino G, bond C, Inch J. Medicines use reviews: the first year of a new community pharmacy service. *Pharm J.* 2007;278:218-223.
29. Bradley F, Wagner AC, Elvey R, Noyce PR, Ashcroft DM. Determinants of the uptake of medicines use reviews (MURs) by community pharmacies in England: A multi-method study. *Health Policy.* 2008;88:258-268.
30. Hann M, Schafheutle EI, Bradley F, et al. Organisational and extraorganisational determinants of volume of service delivery by English community pharmacies: a cross-sectional survey and secondary data analysis. *BMJ Open.* 2017;7.
31. Brown D, Portlock J, Rutter P, Nazar Z. From community pharmacy to healthy living pharmacy: Positive early experiences from Portsmouth, England. *Res Social Adm Pharm.* 2014;10:72-87.
32. Portlock J, Holden M, Patel S. A community pharmacy asthma MUR project in Hampshire and the Isle of Wight. *Pharm J.* 2009;282:109-112.
33. Latif A, Pollock K, Boardman HF. Medicines use reviews: a potential resource or lost opportunity for general practice? *BMC family practice.* 2013;14:57.
34. Latif A, Boardman HF, Pollock K. Understanding the patient perspective of the English community pharmacy Medicines Use Review (MUR). *Res Social Adm Pharm.* 2013;9:949-957.
35. Latif A, Boardman HF, Pollock K. A qualitative study exploring the impact and consequence of the medicines use review service on pharmacy support-staff. *Pharm Pract.* 2013;11:118-124.
36. Wilcock M, Harding G. General practitioners' perceptions of medicines use reviews by pharmacists. *Pharm J.* 2007;279:501-503.
37. Latif A, Waring J, Watmough D, et al. Examination of England's New Medicine Service (NMS) of complex health care interventions in community pharmacy. *Res Social Adm Pharm.* 2016;12:966-989.
38. Lucas B, Blenkinsopp A. Community pharmacists' experience and perceptions of the New Medicines Service (NMS). *Int J Pharm Pract.* 2015;23:399-406.

39. Urban R, Rivers P, Morgan J. Perceptions of medicines use reviews: the views of community pharmacists within a West Yorkshire primary care Trust. *Pharm J*. 2008;281:303-305.
40. Wells KM, Thornley T, Boyd MJ, Boardman HF. Views and experiences of community pharmacists and superintendent pharmacists regarding the New Medicine Service in England prior to implementation. *Res Social Adm Pharm*. 2014;10:58-71.
41. Tucker R. The medicines use review in patients with chronic skin diseases: are pharmacists doing them and how confident are they? *Int J Pharm Pract*. 2013;21:202-204.
42. McDonald R, Cheraghi-Sohi S, Sanders C, Ashcroft D. Professional status in a changing world: The case of medicines use reviews in English community pharmacy. *Soc Sci Med*. 2010;71:451-458.
43. Latif A, Boardman H. Community pharmacists' attitudes towards medicines use reviews and factors affecting the numbers performed. *Pharm World Sci*. 2008;30:536-543.
44. Rutter P, Ramsbottom H, Fitzpatrick R. Community pharmacist perceptions of delivering post-hospital discharge Medicines Use Reviews for elderly patients. *Int J Clin Pharm*. 2017;39:33-36.
45. Merks P, Swieczkowski D, Jaguszewski MJ. Patients' perception of pharmaceutical services available in a community pharmacy among patients living in a rural area of the United Kingdom. *Pharm Pract*. 2016;14:774.
46. Aston J, Wilson KA, Terry DRP. Children/young people taking long-term medication: a survey of community pharmacists' experiences in England. *Int J Pharm Pract*. 2018;26:104-110.
47. Latif A, Tariq S, Abbasi N, Mandane B. Giving Voice to the Medically Under-Served: A Qualitative Co-Production Approach to Explore Patient Medicine Experiences and Improve Services to Marginalized Communities. *Pharmacy (Basel, Switzerland)*. 2018;6.
48. Rodgers RM, Gammie SM, Loo RL, Corlett SA, Krska J. Comparison of pharmacist and public views and experiences of community pharmacy medicines-related services in England. *Patient Prefer Adher*. 2016;10:1749-1758.
49. Hindi A, Parkhurst C, Rashidi Y, Ho SY, Patel N, Donyai P. Development and utilization of the Medicines Use Review patient satisfaction questionnaire. *Patient Prefer Adherence*. 2017;11:1797-1806.
50. Youssef S, Hussain S, Upton D. Do patients perceive any benefit from medicines use reviews offered to them in community pharmacies? *Pharm J*. 2010;284:165-166.
51. Van Den Berg M, Donyai P. A conceptual framework of patient satisfaction with a pharmacy adherence service. *Int J Clin Pharm*. 2014;36:182-191.
52. Latif A, Waring J, Watmough D, Boyd MJ, Elliott RA. 'I expected just to walk in, get my tablets and then walk out': on framing new community pharmacy services in the English healthcare system. *Sociology of health & illness*. 2018;40:1019-1036.
53. van den Berg M, Donyai P. How was patient empowerment portrayed in information leaflets describing the community pharmacy Medicines Use Review service in the UK? *Patient Educ Couns*. 2010;80:274-276.
54. Youssef S, Aspinall V, Upton D. Medicines use review workshops for pharmacy undergraduate students. *Pharm J*. 2009;283:221-222.
55. Harding G, Wilcock M. Community pharmacists' perceptions of medicines use reviews and quality assurance by peer review. *Pharm World Sci*. 2010;32:381-385.
56. van den Berg M, Donyai P. A conceptual framework of patient satisfaction with a pharmacy adherence service. *Int J Clin Pharm*. 2014;36:182-191.
57. James DH, Hatten S, Roberts D, John DN. Identifying criteria for assessing the quality of medicines use review referral documentation by community pharmacists. *Int J Pharm Pract*. 2008;16:365-374.
58. Hamed N, da Costa FA, Horne R, Levitan M, Begley A, Antoniou S. How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants? *Int J Clin Pharm*. 2017;39:1273-1281.



59. Waring J, Latif A, Boyd M, Barber N, Elliott R. Pastoral power in the community pharmacy: A Foucauldian analysis of services to promote patient adherence to new medicine use. *Soc Sci Med.* 2016;148:123-130.
60. Cheema E, Sutcliffe P, Singer DRJ. Community pharmacist-led new medicine service for patients with a long term medical condition: A cross-sectional study. *J. Pharm. Pharm. Sci.* 2017;9:129-133.
61. Morton K, Pattison H, Langley C, Powell R. A qualitative study of English community pharmacists' experiences of providing lifestyle advice to patients with cardiovascular disease. *Res Social Adm Pharm.* 2015;11:e17-29.
62. Ogunbayo OJ, Schafheutle EI, Cutts C, Noyce PR. A qualitative study exploring community pharmacists' awareness of, and contribution to, self-care support in the management of long-term conditions in the United Kingdom. *Res Social Adm Pharm.* 2015;11:859-879.
63. Elvey R, Hassell K, Lewis P, Schafheutle E, Willis S, Harrison S. Patient-centred professionalism in pharmacy: values and behaviours. *J Health Org Man.* 2015;29:413-430.
64. Twigg MJ, Bhattacharya D, Clark A, et al. What do patients need to know? A study to assess patients' satisfaction with information about medicines. *Int J Pharm Pract.* 2016;24:229-236.
65. Latif A. Community pharmacy Medicines Use Review: current challenges. *Integrated pharmacy research & practice.* 2018;7:83-92.
66. Centre for Pharmacy Postgraduate Education & Health Education England. Consultation skills for pharmacy practice: Practice standards for England. <http://www.consultationskillsforpharmacy.com/docs/docc.pdf>; Accessed 05.07.18.
67. The Health Foundation. Person-centred care made simple: what everyone should know about person-centred care: The Health Foundation; 2016.
68. Twigg MJ, Wright D, Kirkdale CL, Desborough JA, Thornley T. The UK Pharmacy Care Plan service: Description, recruitment and initial views on a new community pharmacy intervention. *PloS one.* 2017;12:e0174500.
69. Alonso-Perales MDM, Lasheras B, Beitia G, Beltran I, Marcos B, Nunez-Cordoba JM. Barriers to promote cardiovascular health in community pharmacies: a systematic review. *Health Promot Int.* 2017;32:535-548.
70. NHS England. The NHS belongs to the people: a call to action. London: NHS England; 2013.
71. NHS England. Improving general practice – phase one report. London: NHS England; 2014.
72. Albasri A, Prinjha S, McManus RJ, Sheppard JP. Hypertension referrals from community pharmacy to general practice: multivariate logistic regression analysis of 131 419 patients. *Br J Gen Pract.* 2018.
73. Torjesen I. The Murray review: moving in the right direction. *Pharm J.* 2017;298:Online.
74. Murray R. Community pharmacy clinical services review: NHS England; 2017.
75. de Barra M, Scott CL, Scott NW, et al. Pharmacist services for non-hospitalised patients. *Cochrane Database of Systematic Reviews.* 2018.